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Recurrent refractory arterial thromboembolism
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We report two patients with peripheral vascular disease requiring multiple bilateral radiologic and surgical interventions,
and whose disease was unresponsive to conventional anticoagulation and antiplatelet therapy. Although thrombocytosis
was only intermittent, analysis of the Janus kinase 2 (JAK2) gene revealed a V617F mutation, thus confirming the
presence of an underlying occult myeloproliferative disorder. We propose that JAK2 mutation analysis be considered in
patients with recurrent, unexplained arterial events to identify those with occult myeloproliferative disorders. ( J Vasc
Surg 2009;49:211-3.)Two patients with recurrent arterial thromboembolism
are presented whose disease appeared initially resistant to
conventional medical, radiologic, and surgical interven-
tion. Full blood count indicators, including the platelet
count, were frequently at normal levels. Analysis of the
Janus kinase 2 (JAK2) gene revealed a V617F mutation
enabling a diagnosis of an occult myeloproliferative disor-
der (MPD). The initiation of cytoreductive therapy re-
sulted in stabilization of the secondary peripheral vascular
disease, with no further ischemic events.
CASE REPORTS
Patient 1. A 51-year-old man presented with a critically isch-
emic right foot and gangrene of his hallux and fourth toe. He was a
heavy smoker but had no other cardiovascular risk factors. Both right
pedal pulseswere impalpable; otherwise, examinationwere unremark-
able. The platelet count was mildly elevated at 542 109/L, hemo-
globin (Hb) was 11.5 g/dL, and white blood cell (WBC) count was
12.2  109/L (reference range: platelets, 150-450  109/L; Hb,
13-16 g/dL; WBC, 4-11 109/L).
Duplex ultrasonography revealed a long-segment occlusion of
the right tibioperoneal trunk and an occlusion of the distal posterior
tibial artery; arterial flow in the left leg was normal. The angiogram
revealed no abnormalities proximal to the right tibioperoneal trunk.
The findings were consistent with in situ thrombosis.
After angioplasty of the occlusions and amputation of the
nonsalvageable toes, the patient’s pedal pulses were restored, and
he was discharged with warfarin and clopidogrel. Echocardiogra-
phy and a 24-hour electrocardiogram study detected no underly-
ing cardiac abnormality. Duplex sonography showed the abdomi-
nal aorta to be nonaneurysmal.
The patient returned to the clinic 11 months later with rest
pain of the same (right) foot, which had occurred over a few weeks,
and a necrotic third toe. Angiography revealed stenosis and occlu-
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Vascular Surgery.doi:10.1016/j.jvs.2008.07.007sion of the distal superficial femoral and proximal popliteal arteries,
which were angioplastied. Reocclusion of the tibioperoneal trunk
was noted, which this time could not be crossed.
No improvement in symptoms or pedal Doppler waveforms was
seen after angioplasty. Consequently, an autologous femoroposterior
tibial bypass graft using reversed great saphenous vein was performed.
Postoperative imaging revealed graft thrombosis 48 hours. After
technically successful thrombectomy and vein patch angioplasty of the
graft, duplex scans 1 day postoperatively demonstrated graft reocclu-
sion. Unrelenting pain and failure to heal of the areas of tissue loss
necessitated a right below knee amputation.
The patient returned 2 years later with rest pain and necrosis of
two left toes, despite continuing warfarin and clopidogrel. The
international normalized ratio (INR) had been maintained at 2 to
3 throughout this period and was therapeutic at both representa-
tions. He had continued smoking despite cessation advice.
Duplex imaging revealed evidence of multiple arterial emboli
within the distal superficial femoral and proximal popliteal arteries.
After an angioplasty, which failed to restore blood flow, surgical
thrombectomy retrieved fresh thrombus. Multiple, successive
débridements of nonviable tissue were subsequently required.
Patient 2. A 58-year-old man was referred with rest pain of
the left calf. He had been treated for Hodgkin disease 30 years
previously, including radiotherapy to the left distal femur. No
other vascular risk factors were identified. Results of the full blood
count were abnormal, with Hb at 15.2 g/dL, WBC count at
14.48  109/L, and platelets at 478 109/L, although results of
later repeated tests were within normal limits.
Magnetic resonance angiography revealed a long-segment
occlusion of the left superficial femoral artery, with no significant
disease elsewhere in either leg. Aspirin therapy was commenced. A
polytetrafluoroethylene (PTFE) bypass graft from the superficial
femoral artery to the below knee popliteal artery was performed
electively, owing to a lack of suitable veins.
The patient presented on three separate occasions during the
next 6 months, each time with an acutely painful, cold left foot.
Every time graft thrombosis was confirmed by duplex sonography.
Three separate emergency revascularization procedures were un-
dertaken, the first of which was a successful radiologic thrombol-
ysis of the graft.
On the second presentation, the graft had thrombosed through-
out its entirety and was redone from the superficial femoral to the
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atively, the new graft had thrombosed, and a graft thrombectomy and
patchplasty was performed. On the third presentation, duplex sonog-
raphy revealed proximal graft occlusion with no flow throughout the
graft; another graft thrombectomy was performed.
Every surgical and radiologic revascularization procedure pro-
ceeded successfully and without complication. On every occasion,
the entire thrombus seemed to have been successfully removed at
the time of surgery: postoperative duplex sonography showed the
revascularized graft was patent with good velocities and no steno-
sis. The patient was always fully anticoagulated postoperatively,
and was discharged with aspirin and warfarin.
Eight months after first presenting, his symptoms recurred for a
fourth time, and duplex imaging confirmed reocclusion of the graft.
Further surgical intervention was deemed unlikely to be successful,
and he was managed conservatively. Anticoagulation was withdrawn
given the lack of efficacy in preventing graft reocclusion.
Both patients underwent prothrombotic screening for lupus
anticoagulant and anticardiolipin antibodies, and the results were
negative in both cases. Further investigation was undertaken due
to the atypical nature of the recurrent thromboembolic events and
lack of response to combined antiplatelet and anticoagulant ther-
apy. Sequence-specific polymerase chain reaction revealed a V617F
mutation in the JAK2 gene, confirming the presence of a previ-
ously unsuspected and undetected MPD. A review of serial blood
counts from the preceding 2 years, in both patients, revealed an
intermittent thrombocytosis, with platelet counts up to 811 
109/L in patient 1 and 706  109/L in patient 2, but the classic
hematologic markers of a MPD were not present.
Patient 1 was further investigated with a bone marrow biopsy
that revealed erythroid hypoplasia but normal granulopoiesis and
megakaryopoiesis. Results of cytogenetic analysis were normal.
Both patients commenced appropriate cytoreductive therapy
in the form of hydroxyurea, in addition to further anticoagulation
with warfarin for a target INR of 2.5. No further events have been
documented in either patient, with 2 to 6 months of follow-up,
and both remain under regular hematologic follow-up.
DISCUSSION
Thrombosis is a major cause of morbidity in MPDs: it
represents the initial presentation for 12% to 39% of patients
with essential thrombocythemia (ET) and polycythemia vera
(PV), and thrombosis will develop in many more.1 Histori-
cally these conditions were identified on bone marrow histo-
morphology, which was often nondiagnostic; the recent de-
scription of the JAK2 mutation has greatly transformed
diagnosis of MPD.2 The V617F somatic mutation in the
JAK2 gene, which is involved in cellular signalling, causes the
substitution of phenylalanine for valine at position 617, result-
ing in constitutional activation and consequent cellular prolif-
eration.3,4 The JAK2 mutation has been found in 90% PV
patients and in about 50% ET patients.5 It has also been
reported in associationwithmyelofibrosis2,3 and in subgroups
of myelodysplasia with isolated 5q deletion6 and chronic my-
elomonocytic leukemia.7
Recent evidence indicates that the JAK2 V617F muta-
tion might confer a prothrombotic phenotype.8 ET patients
with the JAK2 V617F mutation, compared with those withthe wild type genotype, are at significantly increased risk of
thrombosis9 to a level approaching the risk associated with
PV.10 A recent review recognizes the tight association be-
tween abdominal and cerebral vein thrombosis and the JAK2
V617Fmutation, despite lack of other hematological features
of MPD.11 It is evident that patients with the JAK2 V617F
mutation may have thrombotic complications even in the
absence of other clinical or laboratory evidence of MPD
(occult MPD) and that thrombosis may occur years before
hematological features of MPD (thrombocytosis, erythrocy-
tosis, splenomegaly) arise.12
These patients manifested a highly prothrombotic state
with recurrent arterial thromboembolic events resistant to
conventional therapy. Because their blood counts were
frequently entirely within normal ranges, the diagnosis of
MPD was not immediately apparent. On other occasions
the moderate thrombocytosis was ascribed to a reactive
postoperative thrombocytosis or infection. The classic di-
agnostic criteria for a MPD were not met (lack of sustained
thrombocytosis or polycythemia, and the unremarkable
bone marrow biopsy), and other thrombophilic disorders
had been excluded.
The availability of a new test in the form of JAK2 muta-
tion analysis enabled the diagnosis of occultMPD to bemade
despite the lack of typical blood count andmarrow features. It
might be difficult in the acute phase to differentiate histolog-
ically between a reactive marrow and that ofMPD;moreover,
the disease might transit from a proliferative to a fibrotic
phase, masking the original diagnosis. Once the diagnosis of
occult MPD was reached, these patients were treated with
appropriate cytoreductive therapy in addition to anticoagula-
tion and antiplatelet therapy to lessen the risk of recurrence.
Stabilization of the arterial disease and lack of further events in
patient 1 after the introduction of cytoreductive therapy fur-
ther support this view.
Existing data in patients with idiopathic thrombosis indi-
cate that the JAK2 mutation does not occur commonly.13
Therefore, JAK2 mutation analysis should not be incorpo-
rated into routine thrombophilia screening; however, it
should be considered in patients with recurrent unexplained
arterial events, refractory to usual intervention, to identify
those with possible occult MPD. The index of suspicion
would of course be higher if the patient displayed persistent
elevations of blood count even though these might be mod-
est. These patients need to be followed up carefully by a
hematologist as some will develop overt clinical MPD years
after the original thrombotic event.
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